| Name | Value |
|---|---|
| Revenues | 303.7K |
| Cost of Revenue | 34.8K |
| Gross Profit | 268.9K |
| Operating Expense | 2,344.6K |
| Operating I/L | -2,069.2K |
| Other Income/Expense | -6,714.5K |
| Interest Income | 0.0K |
| Pretax | -8,783.7K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -8,783.7K |
Blue Water Vaccines, Inc. is a biotechnology company specializing in the research and development of vaccines to prevent infectious diseases globally. The company's lead vaccine programs, BWV-101 and BWV-102, are in preclinical development for influenza and H1 pre-pandemic vaccines, respectively. Additionally, it has a pipeline of other preclinical programs targeting streptococcus pneumoniae induced acute otitis media, norovirus-rotavirus, and norovirus-malaria. Blue Water Vaccines generates revenue through the development and potential commercialization of these vaccines to address critical public health needs.